Genentech and
Seattle Genetics have announced an agreement involving the development and commercialization of a humanized
monoclonal antibody for treating hematologic malignancies, including multiple
myeloma, chronic lymphocytic leukemia, and non-Hodgkin's lymphoma. The antibody, SGN-40, is currently in Phase I
and II clinical trials. According to the
press release, Seattle Genetics will receive $60 million in up-front payment,
and may receive more than $800 million in milestone payments and increasing
royalties on sales of SGN-40 in the future.
Jason Derry, Ph.D., who graduated with honors from DePaul University College of Law, is a molecular biologist and founding author of Patent Docs.
Comments